Articles tagged with Mrna Vaccines
Researchers at Nagoya University developed a new delivery vehicle for circular RNA (cirRNA) using a novel lipid nanoparticle, FL0445-LNP, which improves the stability and efficacy of mRNA-based therapeutics. The technology has potential applications in cancer vaccines, genome editing, and protein supplements.
Researchers have discovered compact viral RNA elements that can stabilize mRNA, increasing protein production. These elements, called tailons, work by extending the poly(A) tail of mRNA, slowing its degradation. This breakthrough offers a simple way to develop longer-lasting and more efficient mRNA technologies for various applications.
A global vaccine trial evaluated fractional doses of COVID-19 boosters, finding they produced strong immune responses comparable to full-dose boosters. This could lead to extended vaccine supplies, improved equity in vaccination programs and reduced costs, especially in low-income countries.
Computer scientists have developed a new AI tool called RNAbpFlow that can map RNA structures with high accuracy, rivaling Google's AlphaFold 3. The method uses flow matching and can generate complete 3D structures from scratch, making it useful for drug discovery and targeting specific RNA folds.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
A new study of over 3 million adults found that booster vaccines reduced the risk of COVID-19-related hospitalization and death. The effectiveness was similar for Moderna and Pfizer-BioNTech booster vaccines, but protection declined over time.
A survey by the Annenberg Public Policy Center found that a strong majority of Americans view the MMR vaccine as safe relative to other vaccines. However, the number of people holding this view is below the threshold required for community immunity, which is worrisome.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
A Purdue-developed mRNA therapy delivery system has shown promise in targeting bladder cancer cells with improved efficiency. The system, called LENN, can be freeze-dried and stored for several days without losing its biological activity.
Researchers developed a new system that efficiently transfects targeted immune cells, supports antigen presentation and immune cell maturation, and successfully crosses the mucus barrier in lung models. This breakthrough offers a promising alternative to lipid nanoparticles for next-generation pulmonary mRNA vaccines.
The CDC recommends shared clinical decision-making for some childhood vaccinations, allowing parents to choose or skip certain vaccines. However, a survey found that many Americans are unclear about what this means and who can be included as health care providers in the discussion.
A new survey by the Annenberg Public Policy Center finds a small but significant drop in the proportion of the public that would recommend getting the MMR vaccine, citing concerns over its safety and effectiveness. The survey also shows declines in perceived safety and effectiveness for other vaccines, such as seasonal flu and Covid-19.
A new white paper by biostatistician Professor Jeffrey S. Morris analyzes the multicomponent US vaccine safety monitoring system, including VAERS and other components. The study suggests improvements to enhance the system's effectiveness and sustain a robust safety monitoring infrastructure.
The partnership aims to co-develop and evaluate next-generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. Apriori's Octavia platform will be combined with A*STAR IDL's saRNA delivery technology to develop improved H5 influenza vaccines that anticipate infection in humans.
Patients receiving mRNA-based COVID vaccines showed improved survival rates and responses to immunotherapy, especially in 'cold' tumors with low PD-L1 expression. The study suggests that these vaccines can reprogram immune responses against cancer, potentially improving outcomes for patients with treatment-resistant disease.
A new mRNA cancer vaccine platform has been developed using a hydrogel-based approach that actively recruits immune cells. This improves efficiency and leads to stronger antitumor immune responses in preclinical models. The research is still in its early stages, but it holds promise for future cancer treatments.
A recent survey found that only 38% of US adults recommend taking a Covid-19 vaccine during pregnancy, while only 42% believe it is safe. Women aged 18-49 are even less likely to support vaccination, with 36% and 28% respectively, suggesting a decline in vaccination rates among childbearing women.
Yale researchers have created a molecular vaccine platform that guides mRNA vaccines to the cell surface, stimulating a stronger immune response. The technology has shown promising results in laboratory experiments against mpox, HPV, and varicella-zoster virus.
A new study by Michigan Medicine University of Michigan researchers concludes that broad COVID-19 vaccination in adults saves the US more money than it spends, with significant economic benefits for those over 65 and middle-aged adults. The model focuses on preventing deaths, hospitalizations, and lost productivity.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
A modeling study finds that COVID-19 vaccination is more cost-effective for individuals aged 65 and above, with favorable results across different parameter input scenarios. The study's findings support the Advisory Committee on Immunization Practices' decision to recommend vaccination with the 2023-2024 mRNA vaccines.
Australian researchers have visualised a key protein complex in malaria parasites for the first time, uncovering a new target for next-generation vaccines. The discovery has led to the development of a promising mRNA vaccine candidate that stops the malaria parasite from reproducing inside mosquitoes, breaking the cycle of transmission...
Researchers discovered that subtle differences in molecular structure can significantly affect mRNA-based drug performance. The study found that optimizing stereoisomers of ionizable lipids like ALC-315 could lead to safer vaccines, as the (S,S)-form delivers mRNA efficiently with reduced toxicity.
A nationwide cohort study of 1 million adults found no increased risk of 29 adverse events after vaccination with the updated COVID-19 mRNA vaccine containing the SARS-CoV-2 Omicron JN.1 lineage. The study provides reassuring safety data on the new vaccine, which has been widely adopted in response to the Omicron variant
Researchers have discovered a way to enhance the effectiveness of mRNA vaccines by disguising them as virus-like particles, prompting a stronger immune response in mice. The innovation could lead to lower doses and longer-lasting immunity.
Scientists have modified mRNA vaccines to include the cytokine IL-12, enhancing T cell responses and improving protection against diseases such as SARS-CoV-2, influenza, melanoma, and listeria infection. The study's findings suggest a promising approach to enhance immune stimulation against cancer and other pathogens.
A study by researchers at the University of Arizona Health Sciences found that vaccinated people generated an overall protective immune response to Delta and Omicron strains, with slightly fewer antibodies for the mutated parts of the virus. The research suggests that immune changes due to antigenic imprinting may not be a significant ...
The BNT162b2 vaccine not only targets the COVID-19 virus but also helps reduce and control innate inflammation to other bacterial and fungal pathogens. By reprogramming innate immune cells, the vaccine reduces pro-inflammatory mediators, providing potential benefits beyond its primary target.
The companies have created a microfluidic device-based LNP production system that enables precise control over particle size, addressing previous productivity issues. The system can produce various types of LNPs in small-batch or mass quantities, from personalized medicine to vaccines for infectious diseases.
The Vaccine Innovation Center at Korea University's College of Medicine successfully held the 2025 Vaccine Expert Training Program, attended by over 380 experts and researchers from various fields. The program aims to foster domestic vaccine R&D experts and promote the development of commercially available vaccines.
Researchers have discovered a key cellular mechanism regulating mRNA vaccine delivery and stability, proposing a new paradigm for mRNA therapeutics. The study highlights the importance of N1-methylpseudouridine modification in enhancing mRNA vaccine effectiveness.
Researchers found that mRNA-based COVID-19 vaccines cause persistent epigenetic changes in monocyte-derived macrophages, enabling a sustained immune response. These changes were preserved for six months after vaccination and required multiple doses to maintain long-term immunity.
A groundbreaking study published in eBioMedicine has shown that a new mRNA vaccine is effective in boosting immunity against tuberculosis. The vaccine demonstrated potent immune responses in infected mice and improved long-term protection when combined with the BCG vaccine.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
A recent study by Emory University researchers found that mRNA vaccines developed to fight COVID-19 are less effective in patients with autoimmune diseases like lupus. The findings highlight the importance of developing tailored vaccination strategies for this vulnerable population.
Researchers developed a new system, MEMPHIS, that models mRNA vaccine responses in a dish, providing insight into vaccine activity in vulnerable populations. The study found muted innate immune responses in people over age 60, indicating an impaired ability to support Th1 immunity.
Researchers found that repeated mRNA vaccines enhance mucosal antibodies in nasal secretions, blocking viral entry and providing sustained protection. The immune responses generated by mRNA vaccines may persist longer than previously thought, offering hope for sustained protection against emerging COVID-19 variants.
Researchers at Penn Medicine have developed the first mRNA vaccine against C. difficile, a bacterium that causes severe diarrhea and colon damage. The vaccine induces a robust immune response, promotes clearance of existing bacteria from the gut, and overcomes deficits in host immunity to protect against infections.
Researchers at Nagoya University developed an innovative synthesis technology to produce high-purity, fully chemically synthesized mRNA. This breakthrough cuts down the production time and can be used to address concerns about purity and speed in mRNA vaccine development.
A study analyzed blood samples from individuals who received an mRNA vaccine booster to understand its circulation and breakdown in the bloodstream. The research found that higher levels of mRNA and fatty nanoparticles were linked to increased anti-PEG antibodies, suggesting potential issues with future mRNA treatments.
A nationwide Swedish study found that full vaccination significantly reduced the risk of severe cardiovascular outcomes linked to COVID-19, such as heart attack and stroke. However, temporary increases in cardiovascular risk were observed after individual doses, particularly among elderly and males.
A new mpox mRNA vaccine has shown improved responses in nonhuman primate models, reducing symptoms and disease duration compared to a currently licensed modified vaccinia Ankara (MVA) vaccine. The investigational vaccine resulted in fewer lesions, shorter disease duration, and lower viral shedding.